Linda Stocum, Associate Editor

This week's edition of the Mainstream Patients features stories about FDA's latest approval, abortion, and more.

Eric Simpson, MD, MCR, director of clinical research and dermatology professor at the Frances J. Storrs medical school at Oregon Health & Science University in Portland, Oregon, explains dives into what 2022 is bringing to the AD space.

Eric Simpson, MD, MCR, director of clinical research and dermatology professor at the Frances J. Storrs medical school at Oregon Health & Science University in Portland, Oregon, explains what allied health care workers can learn from his presentation.

Eric Simpson, MD, MCR, director of clinical research and dermatology professor at the Frances J. Storrs medical school at Oregon Health & Science University in Portland, Oregon, details the environment factors that could impact atopic dermatitis.

Here is what to expect from the “Getting to the Roots of Childhood Atopic Dermatitis” live virtual webinar happening June 23, 2022, at 6:00 PM EST.

Barbara McElroy, MSN, CRNI, VA-BC, shares her expert knowledge on placing IVs and treating patients to help health care workers optimize this procedure at the 2022 National Infusion Center Association Annual Conference.

Lindsey Savickas, RN, BSN, and COO at Infusion Associates, explains how infusion centers can support researchers in the dermatology space in discovering more effective treatments.

Barbara McElroy, MSN, CRNI, VA-BC, explains the responsibility a nurse has to their patient and how the Nurse Practicing Act needs to be more well-known.

Knowing advocacy types and how to get patients involved in advocating for themselves is a key topic in the medical world as drug access can become a confusing issue to tackle. A group of panelists at the 2022 NICA Annual Conference explained how clinicians can help their patients.

At the 2022 National Infusion Center Association Annual Conference, Kelly Gordon, PharmD, answered why diagnosing GPP is so difficult and what to look for to optimize patient care.

Lindsey Savickas, RN, BSN, and COO at Infusion Associates, explains how infusion centers and dermatologists are going to work together more as medications become more advanced.

Brian Nyquist, MPH, the CEO of the National Infusion Center Association (NICA), talks on the engaging sessions happening this weekend at the NICA conference and its growing importance to the dermatology community.

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, who discusses the importance of multidisciplinary in the dermatology specialty.

Amy Paller, MD, chair of the Department of Dermatology at Northwestern University’s Feinberg School of Medicine, sits down to answer the important questions on this FDA approval.

This week's edition of the Mainstream Patients features stories about skin care for trans women, Aztec clay for the skin, and more.

This marks the first FDA approval of a systemic treatment for alopecia areata.

ICYMI, this week we had stories from the 2022 Fall Clinical Dermatology Conference for PAs & NPs, FDA's approval of dupilumab, and more.

A recent study dove into how precision medicine can be used to better target inflammatory skin disease and provide physicians with better treatment regimens.

Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis

Joshua Zeichner, MD, discusses how important it is to treat acne properly and gives a tip about moisturizers and topical retinoids.

About 80% of patients treated with roflumilast foam 0.3% (ARQ-154, Arcutis Biotherapeutics Inc) met the primary endpoint of the trial.

Kenneth J. Tomecki, MD, discussed the clinical relevance of sexually transmitted diseases (STDs) to dermatology and outlined what to look for and how to treat various conditions at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.

In a hard-hitting session from the 2022 Fall Clinical Dermatology Conference for PAs & NPs, April Armstrong, MD, MPH, dove into PAD technology and future innovations in psoriasis treatment.

ICYMI, this week we had stories from the trending skin care from May, FDA's newest pipeline move, and more.

Regeneron Pharmaceuticals Inc came to an agreement to buy the drug from Sanofi for up to $1.1 billion.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of May.

This week's edition of the Mainstream Patients features stories about heat rash, drinking Aloe Vera juice, and more.

Timber Pharmaceuticals has received an FDA breakthrough therapy designation for TMB-001 for the treatment of congenital ichthyosis.

Dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals, Inc) has received priority review for its supplemental Biologics License Application by the FDA to treat adult patients with prurigo nodularis.

ICYMI, this week we had stories from the about precision medicine, FDA's newest approval, and more.